IN THE CLAIMS

26. *(Three Times Amended)* A method for inducing antibody production in an animal against a self-protein of that animal, the method comprising, administering, to the animal, an immunologically effective amount of an immunogenic composition comprising at least one modified self-protein and at least one immunologically acceptable adjuvant wherein the modified self-protein is modified by [substituting one or more] containing a substitution of at least one peptide fragment[s] of the self-protein [by] with a [corresponding number of] peptide[s each] containing at least one immunodominant T-cell epitope which is foreign to the animal[species], said substitution being carried out so as to essentially preserve the overall tertiary structure of the unmodified self protein.

46. *(Amended)* The method according to claim 26, wherein said immunodominant foreign T-cell epitope is [inserted] substituted in so as to preserve [flanking regions] amino acid sequences from the original self-protein on both sides of the T-cell epitope.

Please add the following new claims:

--47. The method according to claim 26, wherein the modified self-protein is selected from the group consisting of modified tumor necrosis factor alpha (TNF-α), modified tumor necrosis factor beta (TNF-β), modified gamma interferon (γ-interferon), modified interleukin 1 (IL-1), and modified immune globulin E (IgE).

48. The method according to claim 47, wherein the modified self-protein is selected from the group consisting of modified TNF-α and modified γ-interferon, and wherein the antibodies produced are effective in treating or ameliorating cachexia.

49. The method according to claim 47, wherein the modified self-protein is selected from the group consisting of modified TNF-α, modified TNF-β, and IL-1, and wherein the antibodies produced are effective in treating or ameliorating chronic inflammatory disease.

50. The method according to claim 49, wherein the chronic inflammatory disease is selected from the group consisting of rheumatoid arthritis and inflammatory bowel disease.

51. The method according to claim 47, wherein the modified self-protein is modified TNF-α and wherein the antibodies produced are effective in treating or ameliorating diabetes mellitus.

52. The method according to claim 47, wherein the modified self-protein is modified IgE and wherein the antibodies produced are effective in treating or ameliorating allergy.

--

REMARKS

A Petition for Extension of Time of one month is filed concurrently herewith, extending the due date for reply to November 14, 1999.